<DOC>
	<DOCNO>NCT01917630</DOCNO>
	<brief_summary>To determine effect 12 week administration different dose level ALV003 mucosal line small intestine symptom celiac disease patient .</brief_summary>
	<brief_title>Evaluation Efficacy Safety ALV003 Symptomatic Celiac Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Ages 18 80 year Physician diagnose celiac disease Adherence glutenfree diet Experiencing symptom celiac disease 1month period Willing take study medication 12 week Willing comply study procedure Sign inform consent Active inflammatory bowel disease Active dermatitis herpetiformis Use certain specific medication prior entry History alcohol illicit drug abuse previous 6 month Pregnant lactate Received experimental drug within 30 day enrollment Uncontrolled chronic disease condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Celiac disease</keyword>
	<keyword>Gluten-free diet</keyword>
	<keyword>Coeliac disease</keyword>
	<keyword>Celiac sprue</keyword>
</DOC>